A carregar...
Clinical Overview of MDM2/X-Targeted Therapies
MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation and inhibiting its transcriptional activity. Both MDM2 and MDMX function as powerful oncogenes and are commonly ove...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4728205/ https://ncbi.nlm.nih.gov/pubmed/26858935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2016.00007 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|